What is Merus?
Founded in 2003, Merus is dedicated to advancing cancer treatment through its proprietary Multiclonics® platform. This technology enables the development of novel antibody therapeutics designed to offer enhanced efficacy and specificity. The company's pipeline focuses on full-length bispecific and trispecific antibodies, which are manufactured using standard industry processes and exhibit characteristics similar to conventional monoclonal antibodies, including extended half-life and low immunogenicity, as demonstrated in preclinical and clinical studies.
How much funding has Merus raised?
Merus has raised a total of $60M across 1 funding round:
Stock Offering
$60M
Stock Issuance/Offering (2016): $60M, investors not publicly disclosed
What's next for Merus?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Merus. This capital infusion is expected to accelerate the clinical development of its bispecific and trispecific antibody candidates, potentially advancing them through late-stage trials and towards commercialization. The company's focus on innovative oncology therapeutics positions it to address significant unmet needs in cancer care, with future growth likely centered on expanding its pipeline and forging strategic partnerships.
See full Merus company page
